ASCO guidelines have been updated to include apixaban and rivaroxaban for extended VTE prophylaxis after cancer surgery, and apixaban for VTE treatment.
Answers are grounded in this paper and cite their sources.
Expands NOAC options for extended VTE prophylaxis after cancer surgery and for VTE treatment; incorporates RCT evidence into updated ASCO guidelines.
Apixaban and rivaroxaban were added as options for extended pharmacologic thromboprophylaxis after cancer surgery, with a weak strength of recommendation. Apixaban was also added as an option for the treatment of VTE, with high quality of evidence and a strong recommendation.Additional information is available at www.asco.org/supportive-care-guidelines.
No takes yet. Share an insight, caveat, or question.
Key et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: